Evaluation of PPAR-α, PPAR-γ, TLR2, TLR4 Gene Expression In Patients with Coronary Artery Disease (CAD): An

Mahbobe Abbasluo1, Mahya Bakhshi Ardakani2, Negar Jafari3

  • 1Department of Biology, Islamic Azad University, Ashkezar Branch, Ashkezar, Iran.

Insights

Toll-like receptors 2 (TLR2) and 4 (TLR4) show increased mRNA expression in coronary artery disease (CAD) patients. While PPAR-α and PPAR-γ genes were upregulated, their expression differences were not significant, suggesting TLR2 and TLR4

Area of Science:

  • Immunogenetics
  • Cardiovascular Research
  • Molecular Medicine

Background:

  • Coronary artery disease (CAD) pathogenesis involves complex inflammatory and immune responses.
  • The roles of Toll-like receptors (TLRs) and Peroxisome proliferator-activated receptors (PPARs) in CAD are not fully elucidated.
  • Investigating specific gene expression offers insights into CAD mechanisms.

Purpose of the Study:

  • To compare the mRNA expression of TLR2, TLR4, PPAR-α, and PPAR-γ genes in CAD patients versus healthy controls.
  • To elucidate the involvement of these genes in the innate immune pathway within CAD.

Main Methods:

  • A case-control study involving 12 CAD patients and 10 healthy controls.
  • Real-Time PCR was used to quantify mRNA expression levels of TLR2, TLR4, PPAR-α, and PPAR-γ.
  • Statistical analysis included t-tests and non-parametric tests with a significance level of P<0.05.

Main Results:

  • Significantly higher mRNA expression of TLR2 and TLR4 was observed in CAD patients compared to controls (P=0.001).
  • PPAR-α and PPAR-γ genes showed upregulation in patients, but the difference was not statistically significant between groups.
  • These findings highlight the differential involvement of TLRs and PPARs in CAD.

Conclusions:

  • TLR2 and TLR4 play a significant role in the pathogenesis of coronary artery disease.
  • The study supports the hypothesis that TLR2 and TLR4 could be potential therapeutic targets for CAD.
  • Further research is warranted to explore the therapeutic potential of targeting TLR2 and TLR4 in CAD management.
Abstract